Acetylator Status Among Newly Diagnosed and Recurrent Tuberculosis Patients from Kupang, Eastern Part of Indonesia

References

• World Health Organization. Global Tuberculosis Report 2019. Geneva: World Health Organization; 2019.
   Google Scholar
• Chakraborty S, Rhee KY. Tuberculosis Drug Development: history and Evolution of the Mechanism-Based Paradigm. Cold Spring Harb Perspect Med. 2015;5(8):a021147. doi:10.1101/cshperspect.a021147
   PubMed Web of Science ®Google Scholar
• Comstock GW, Golub JE, Panjabi R. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis. 2007;11(8):828–837.
   Web of Science ®Google Scholar
• Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med. 2012;5:89–98. doi:10.2147/PGPM.S15454
   PubMedGoogle Scholar
• Das RP, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics. 2008;9(3):311–321. doi:10.2217/14622416.9.3.311
   Web of Science ®Google Scholar
• Werely CJ, Donald PR, van Helden PD. NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients. Per Med. 2007;4(2):123–131. doi:10.2217/17410541.4.2.123
   Web of Science ®Google Scholar
• Wang P, Pradhan K, Zhong X-B, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6(5):384–392. doi:10.1016/j.apsb.2016.07.014
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55(2):169–177. doi:10.1093/cid/cis353
   PubMed Web of Science ®Google Scholar
• Yuliwulandari R, Prayuni K, Susilowati RW, et al. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in Indonesian population. Pharmacogenomics. 2019;20(18):1303–1310. doi:10.2217/pgs-2019-0131
   PubMed Web of Science ®Google Scholar
• Yuliwulandari R, Susilowati RW, Razari I, Viyati K, Umniyati H, Prayuni K. N-acetyltransferase 2 polymorphism and acetylation profiles in Buginese ethnics of Indonesia. Ann Hum Genet. 2019;83(6):465–471. doi:10.1111/ahg.12341
   Web of Science ®Google Scholar
• Kementerian Kesehatan Republik Indonesia. Evaluasi Program Tuberkulosis 2018 Dan Upaya Menuju Eliminasi Tuberkulosis 2030. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019.
   Google Scholar
• Millet JP, Orcau À, De Olalla PG, Casals M, Rius C, Caylà JA. Tuberculosis recurrence and its associated risk factors among successfully treated patients. J Epidemiol Community Health. 2009;63(10):799–804. doi:10.1136/jech.2008.077560
   Web of Science ®Google Scholar
• Parwati I, van Crevel R, Sudiro M, et al. Mycobacterium tuberculosis population structures differ significantly on two Indonesian Islands. J Clin Microbiol. 2008;46(11):3639–3645. doi:10.1128/JCM.00605-08
   PubMed Web of Science ®Google Scholar
• Sahiratmadja E, Penggoam S, Maskoen AM, et al. Distribution of rs1801279 and rs1799930 polymorphisms in NAT2 gene among population in Kupang, Nusa Tenggara Timur, Indonesia. Indones Biomed J. 2018;10(1):56–61. doi:10.18585/inabj.v10i1.330
   Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018.
   Google Scholar
• Moosazadeh M, Bahrampour A, Nasehi M, Khanjani N. The incidence of recurrence of tuberculosis and its related factors in smear-positive pulmonary tuberculosis patients in Iran: a retrospective cohort study. Lung India. 2015;32(6):557–560. doi:10.4103/0970-2113.168113
   Google Scholar
• Mutembo S, Mutanga JN, Musokotwane K, et al. Urban-rural disparities in treatment outcomes among recurrent TB cases in Southern Province, Zambia. BMC Infect Dis. 2019;19(1):1–8. doi:10.1186/s12879-019-4709-5
   Web of Science ®Google Scholar
• Hermans SM, Zinyakatira N, Caldwell J, Cobelens FGJ, Boulle A, Wood R. High Rates of Recurrent Tuberculosis Disease: a Population-level Cohort Study. Clin Infect Dis. 2020;3–10.
   Web of Science ®Google Scholar
• Zong Z, Huo F, Shi J, et al. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Front Microbiol. 2018;9(8):1–8. doi:10.3389/fmicb.2018.01858
   Web of Science ®Google Scholar
• Korhonen V, Soini H, Vasankari T, Ollgren J, Smit PW, Ruutu P. Recurrent tuberculosis in Finland 1995–2013: a clinical and epidemiological cohort study. BMC Infect Dis. 2017;17(1):721. doi:10.1186/s12879-017-2818-6
   Web of Science ®Google Scholar
• Dooley KE, Lahlou O, Ghali I, et al. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health. 2011;11(1):140. doi:10.1186/1471-2458-11-140
   PubMed Web of Science ®Google Scholar
• Sun Y, Harley D, Vally H, Sleigh A. Impact of multidrug resistance on tuberculosis recurrence and long-term outcome in China. PLoS One. 2017;12(1):1–11.
   Web of Science ®Google Scholar
• Bestrashniy JRBM, Nguyen VN, Nguyen TL, et al. Recurrence of tuberculosis among patients following treatment completion in eight provinces of Vietnam: a nested case-control study. Int J Infect Dis. 2018;74:31–37. doi:10.1016/j.ijid.2018.06.013
   PubMed Web of Science ®Google Scholar
• Igumnova V, Capligina V, Krams A, et al. Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients. J Infect Chemother. 2016;22(7):472–477. doi:10.1016/j.jiac.2016.04.003
   Web of Science ®Google Scholar
• Toure A, Cabral M, Niang A, et al. Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol Reports. 2016;3:826–831. doi:10.1016/j.toxrep.2016.10.004
   Google Scholar
• Forestiero FJ, Cecon L, Hirata MH, et al. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clin Chim Acta. 2013;415:215–219. doi:10.1016/j.cca.2012.10.030
   PubMed Web of Science ®Google Scholar
• Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis. 2007;87(6):551–556. doi:10.1016/j.tube.2007.05.012
   Web of Science ®Google Scholar
• Chen B, Li JH, Xu YM, Wang J, Cao XM. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients. Clin Chim Acta. 2006;365(1):104–108. doi:10.1016/j.cca.2005.08.012
   Web of Science ®Google Scholar
• Susilowati RW, Prayuni K, Razari I, Bahri S, Yuliwulandari R. High frequency of NAT2 slow acetylator alleles in the Malay population of Indonesia: an awareness to the anti-tuberculosis drug induced liver injury and cancer. Med J Indones. 2017;26(1):7–13. doi:10.13181/mji.v26i1.1563
   Web of Science ®Google Scholar
• Mona S, Grunz KE, Brauer S, et al. Genetic admixture history of Eastern Indonesia as revealed by Y-chromosome and mitochondrial DNA analysis. Mol Biol Evol. 2009;26(8):1865–1877. doi:10.1093/molbev/msp097
   Web of Science ®Google Scholar
• Gomes SM, Bodner M, Souto L, et al. Human settlement history between Sunda and Sahul: a focus on East Timor (Timor-Leste) and the Pleistocenic mtDNA diversity. BMC Genomics. 2015;16(1):70. doi:10.1186/s12864-014-1201-x
   PubMed Web of Science ®Google Scholar
• Selinski S, Blaszkewicz M, Getzmann S, Golka K. N-Acetyltransferase 2: ultra-slow acetylators enter the stage. Arch Toxicol. 2015;89(12):2445–2447. doi:10.1007/s00204-015-1650-2
   Web of Science ®Google Scholar
• Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016;45:474–492. doi:10.1016/j.meegid.2016.09.004
   PubMed Web of Science ®Google Scholar
• Unissa AN, Sukumar S, Hanna LE. The Role of N-Acetyl Transferases on Isoniazid Resistance from Mycobacterium tuberculosis and Human: an In Silico Approach. Tuberc Respir Dis (Seoul). 2017;80(3):255–264. doi:10.4046/trd.2017.80.3.255
   Web of Science ®Google Scholar